Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC (CAMELLIA)

A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer

It is a phase III trial to explore the efficacy and safety of metronomic chemotherapy with Capecitabine versus intermittent Capecitabine as maintenance therapy following first-line Capecitabine plus Docetaxel chemotherapy in treatment of HER2-negative metastatic breast cancer(mBC).

Study Overview

• Status: Unknown
• Conditions: Skin Diseases; Neoplasms by Site; Breast Neoplasms; Breast Diseases; Neoplasm Metastasis
• Intervention / Treatment: Drug: Docetaxel plus Capecitabine; Drug: Intermittent Capecitabine; Drug: Metronomic Capecitabine

• Study Type: Interventional
• Enrollment (Anticipated): 280
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100021
    • Recruiting
    • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    • Contact: Binghe Xu, MD, PhD; Phone Number: +86-10-87788826; Email: xubinghe@medmail.com.cn
    • Contact: Fei Ma, MD; Phone Number: +86-13910217780; Email: mafei2011@139.com
    • Principal Investigator: Binghe Xu, MD, PhD
    • Sub-Investigator: Fei Ma, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed informed consent obtained prior to initiation of any study-specific procedures or treatment as confirmation of the patient's awareness and willingness to comply with the study requirements.
• Female patients aged ≥ 18 years.
• Histologically confirmed and documented HER2-negative metastatic breast cancer.
• Previously untreated first-line chemotherapy.
• Patients with at least one measurable lesion according to RECIST criteria at study entry.
• Documented ER/PgR status.
• Prior hormone therapy for metastatic disease is allowed but must stop before study entry.
• KPS>70.
• Life expectancy of ≥12 weeks

Exclusion Criteria:

• Previous chemotherapy for metastatic breast cancer.
• Prior adjuvant/neoadjuvant chemotherapy within 6 months prior to first study treatment administration.
• Prior (radical)radiotherapy for the treatment of metastatic disease or major surgical procedure within 28 days prior to the first study treatment,
• Inadequate bone marrow function: absolute neutrophil count (ANC): <1.5 x 109/L, platelet count<75 x 109/L or hemoglobin <100g/L.

• Inadequate liver or renal function, defined as:

  1. Serum (total) bilirubin >2 x the upper limit of normal (ULN) for the institution
  2. AST/SGOT or ALT/SGPT >2.5 x ULN (>5 x ULN in patients with liver metastases)
  3. ALP >2.5 x ULN at baseline (>5 x ULN in patients with liver metastases).
  4. Serum creatinine>140umol/L.
• Pregnant or lactating females.
• Her-2 positive (ICH +++ or FISH positive).
• Symptomatic cerebral parenchyma and/or leptomeningeal metastases.
• Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
• Pre-existing peripheral neuropathy ≥grade 1 according NCI CTCAE 4.0.
• Mental disease or other conditions affecting on the compliance of patients.

• Other serious disease or medical condition:

  1. History of uncontrolled seizures, CNS disorders or psychiatric disability judged by the Investigator to be clinically significant precluding informed consent.
  2. Congestive heart failure, or unstable angina, myocardial infarction within ≤6 months prior to the first study treatment, uncontrolled hypertension and high risk, uncontrolled arrhythmias.
  3. Uncontrolled acute infection
• Inability to take or absorption oral medications.
• Concurrent or within 30 days using drugs of other clinical trials.
• Previous treatments containing Capecitabine (whether adjuvant or palliative treatment).
• Previous treatments containing docetaxel within 12 months.
• Known hypersensitivity to any of the study treatments or excipients.
• Any other conditions the research consider not appropriate to take part in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Intermittent Capecitabine; Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle.	Drug: Docetaxel plus Capecitabine; Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration. For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.; Drug: Intermittent Capecitabine; Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle; Other Names: Xeloda
Experimental: Metronomic Capecitabine; Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle	Drug: Docetaxel plus Capecitabine; Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration. For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.; Drug: Metronomic Capecitabine; Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle; Other Names: Xeloda

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS)	Time from randomization to progression or death (whichever occurred first).	up to 36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events (AEs)	Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0), premature withdrawals and vital signs. Hand-foot syndrome and diarrhea will be specially interested. Adverse events of special interest: hand-foot syndrome and diarrhea. The estimated HFS rate will be about 60% from intermittent Capecitabine vs about 10% from metronomic Capecitabine, diarrhea rate will be about 50% from intermittent Capecitabine vs about 10% from metronomic Capecitabine.	up to 36 months
Overall survival (OS):	Time from randomization to death	up to 52 months
Overall Response rates (ORR)	Defined as CR+PR, assessed based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. It will be evaluated in the initial treatment phase and the maintenance treatment phase.	up to 36 months
Clinical Benefit rate (CBR)	Defined as CR+PR+SD, assessed based on on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. It will be evaluated in the initial treatment phase and the maintenance treatment phase	up to 36 months
Time to Progression (TTP)	Time from randomization to disease progression	up to 36 months
QoL	Using the EORTC quality of life questionnaire QLQ-C30	up to 36 months

Collaborators and Investigators

• Sponsor: Binghe Xu
• Collaborators: Hoffmann-La Roche
• Investigators: Principal Investigator: Binghe Xu, MD, PhD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Publications and helpful links

General Publications

• Guan X, Ma F, Li C, Wu S, Hu S, Huang J, Sun X, Wang J, Luo Y, Cai R, Fan Y, Li Q, Chen S, Zhang P, Li Q, Xu B. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun (Lond). 2019 Jan 3;39(1):1. doi: 10.1186/s40880-018-0346-4.

Study record dates

Study Major Dates

• Study Start: October 1, 2013
• Primary Completion (Anticipated): July 1, 2020
• Study Completion (Anticipated): July 1, 2021

Study Registration Dates

• First Submitted: July 19, 2013
• First Submitted That Met QC Criteria: August 4, 2013
• First Posted (Estimate): August 6, 2013

Study Record Updates

• Last Update Posted (Actual): July 23, 2020
• Last Update Submitted That Met QC Criteria: July 21, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Keywords: Docetaxel; Capecitabine; Metronomic chemotherapy; Antineoplastic Agents; Metastatic Breast Cancer; Therapeutic Uses; Antimetabolites; Tubulin Modulators; Maintenance chemotherapy
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplastic Processes; Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Skin Diseases; Breast Diseases; Neoplasms by Site; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Docetaxel; Capecitabine
• Other Study ID Numbers: ML28898

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No